Breast Cancer

Fulvestrant submitted for approval in Europe

Published in Cancer Weekly, March 4th, 2003

AstraZeneca announced the submission in Europe of a Marketing Authorization Application for the use of Faslodex (fulvestrant) in the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following prior endocrine therapy.

Faslodex was approved by the U.S. Food and Drug Administration in April 2002.

Faslodex is a novel agent, an antiestrogen with no agonist activity that acts as an estrogen receptor downregulator and is the first in a new class of treatments for breast cancer. It targets, binds to, blocks, and then degrades the estrogen receptors in breast cancer cells unlike aromatase inhibitors, that reduce the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-03-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry